The Carlyle Group and GTCR have agreed to acquire the global Contract Research and Manufacturing Organisation (CRMO) Albany Molecular Research Inc (AMRI).
AMRI CEO, William Marth, commented, "This transaction is a strong endorsement of our strategy. Given their deep healthcare industry expertise and financial resources, Carlyle and GTCR are highly attractive partners for us and offer a compelling opportunity to accelerate our growth and enhance delivery of world-class solutions to our customers."
Acquisitions weren't specifically mentioned, but given AMRI's history (acquiring Euticals last year and Gadea Pharmaceuticals Group in 2015) and the extra financial firepower provided by two private equity backers, the CEO's nod to "accelerated growth" is likely to include further M&A.
AMRI Signs Definitive Agreement To Be Acquired By The Carlyle Group and GTCR for $21.75 per share in cash